HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Year Check-Up: can this injection keep dangerous swelling attacks at bay?
Disease control CompletedThis study observed 48 Polish patients with hereditary angioedema (HAE) who were already receiving lanadelumab injections to prevent sudden, severe swelling attacks. Researchers tracked patients for up to two years to see how many remained attack-free, how often attacks occurred,…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Apr 04, 2026 05:08 UTC
-
Study checks how well two HAE drugs work in everyday chinese patients
Disease control CompletedThis study looked at how well two already-approved drugs work for people with Hereditary Angioedema (HAE) in real-world Chinese medical settings. It followed 115 people to see how often attacks occurred while using lanadelumab (a preventive drug) and how quickly attacks resolved …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Apr 04, 2026 05:06 UTC
-
Doctors track new HAE Treatment's Real-World performance
Disease control CompletedThis study observed 155 people in Japan who were starting treatment with Lanadelumab for hereditary angioedema (HAE), a condition that causes severe swelling attacks. The main goal was to monitor for side effects and see if the treatment helped reduce the number of swelling episo…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for kids with rare swelling disorder
Disease control CompletedThis study tested an investigational medicine called CSL312 (garadacimab) to see if it could safely prevent painful swelling attacks in children aged 2 to 11 with hereditary angioedema (HAE). The medicine was given as a regular injection to see if it could reduce the number of at…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
3-Year study tests Real-World impact of HAE prevention drug
Disease control CompletedThis study followed 140 people with hereditary angioedema (HAE) for up to three years to see how well the drug lanadelumab worked in everyday life. The main goal was to compare the number of HAE attacks people had while on the drug to the number they had before starting it. Parti…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Shire • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Free drug trial offers relief for rare swelling disorder
Disease control CompletedThis study tested the safety and effectiveness of an already-approved drug, icatibant injection, for treating sudden, severe swelling attacks caused by a condition called bradykinin-induced angioedema. It involved 5 adult patients in Taiwan who could not get the drug through thei…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE4 • Sponsor: Nang Kuang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Drug safety watch for kids with rare swelling disorder
Disease control CompletedThis study monitored children and teenagers in Japan who received Icatibant injections to treat sudden attacks of hereditary angioedema (HAE), a condition causing severe swelling. The main goal was to check for side effects and see how well the treatment worked to resolve these a…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC